But compliance -- submitting the right forms at the right time with the right data -- is the floor, not the ceiling. The adverse event data you collect is not merely a regulatory deliverable. It is a clinical dataset that, when examined thoughtfully, reveals patterns about what is happening to participants at your site. And those patterns, once identified, create opportunities to improve care in ways that no amount of timely form submission can achieve.

I want to be precise about the scope of what I am describing. This is not pharmacovigilance signal detection -- that is the sponsor's responsibility, performed across all sites using aggregate data, statistical methods, and medical review teams that the individual site does not have access to. What I am describing is something more immediate and, in my view, equally important: a site-level practice of examining your own safety data for patterns that suggest actionable improvements in how you monitor and care for participants at your site.

The distinction matters. The sponsor asks: "Is this drug causing a safety problem across the trial population?" You ask: "Is something happening at my site that I can understand better and respond to?" Both questions matter. But yours is the one you can act on immediately.

But compliance -- submitting the right forms at the right time with the right data -- is the floor, not the ceiling. The adverse event data you collect is not merely a regulatory deliverable. It is a clinical dataset that, when examined thoughtfully, reveals patterns about what is happening to participants at your site. And those patterns, once identified, create opportunities to improve care in ways that no amount of timely form submission can achieve.

I want to be precise about the scope of what I am describing. This is not pharmacovigilance signal detection -- that is the sponsor's responsibility, performed across all sites using aggregate data, statistical methods, and medical review teams that the individual site does not have access to. What I am describing is something more immediate and, in my view, equally important: a site-level practice of examining your own safety data for patterns that suggest actionable improvements in how you monitor and care for participants at your site.

The distinction matters. The sponsor asks: "Is this drug causing a safety problem across the trial population?" You ask: "Is something happening at my site that I can understand better and respond to?" Both questions matter. But yours is the one you can act on immediately.